^
    Back
    Association details:
    Biomarker:PML-JAK1 fusion
    Cancer:Sarcoma
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.

    Published date:
    05/19/2021
    Excerpt:
    Several rare and novel fusions were identified; a sarcoma with TPM4-NTRK3 fusion responded to larotrectinib, while a sarcoma with PML-JAK1 fusion did not respond to ruxolitinib, and a sarcoma with IL7R-BCL2 fusion progressed on venetoclax.
    DOI:
    10.1200/JCO.2021.39.15_suppl.11538